Cardiosense

Cardiosense, founded in 2020, is a promising player in the intersection of AI, Analytics, Hardware, and Health Care. Headquartered in the United States, the company utilizes its slogan, "Leveraging high-fidelity physiological waveforms to unlock AI-Driven insights in cardiac function," to describe its core mission.

Specializing in developing a physiological waveform data platform, Cardiosense employs novel multi-modal sensors along with state-of-the-art machine learning techniques. The primary goal is to offer predictive biomarkers for pre-symptomatic disease detection and personalized therapy, revealing a strong focus on innovation within the healthcare sector.

In the last recorded investment round, Cardiosense secured a $15.10M Series A investment on 08 December 2022. The funding was backed by significant industry players such as Broadview Ventures, Laerdal Million Lives Fund, Hatteras Venture Partners, Portal Innovation Ventures, UnityPoint Health Ventures, and OSF Ventures, highlighting the firm's notable support network and potential for growth in the burgeoning health-tech sector.